A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML)

Autor:	Oliver Mikse, Tahirih L. Lamothe, Lisa M Olson, Nidhi Jain, Jennifer L. Proctor, Ryan Knihtila, Sean McDonough, John C. Davis, Anthony E. Boitano, Rahul Palchaudhuri, Michael P. Cooke, Ganapathy N. Sarma, Bradley R. Pearse, Prashant raj Bhattarai, Leanne Lanieri, Junia Dushime, Kellie Latimer
Rok vydání:	2021
Předmět:	Transplantation Antibody-drug conjugate Standard of care biology business.industry CD117 Myeloid leukemia Half-life Cell Biology Hematology medicine.disease Leukemia Cancer research medicine biology.protein Molecular Medicine Immunology and Allergy business Amanitin
Zdroj:	Transplantation and Cellular Therapy. 27:S49-S50
ISSN:	2666-6367
DOI:	10.1016/s2666-6367(21)00079-8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1be6db879b36491aaefce34d13b1d033 https://doi.org/10.1016/s2666-6367(21)00079-8 Zobrazit plný text záznamu Full Text from ScienceDirect